Document is current
Any future updates will be listed below
-
Authors
Sharma, Divija
Piontkowski, Austin J.
Ungar, Benjamin
- License Information
-
More Information
Article History
Received: 26 February 2024
Revised: 26 February 2024
Accepted: 7 April 2024
First Online: 25 April 2024
Declarations
:
: Not applicable.
: Approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board (STUDY-22-00884).
: BU is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Incyte, Rapt Therapeutics, and Pfizer. He is also a consultant for Arcutis Biotherapeutics, Bristol Myers Squib, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB.
